IgA nephropathy: Frequent, but rarely diagnosed;IgA-nephropathie: Häufig, jedoch nür selten diagnostiziert

Internist

Volumn 44, Issue 9, 2003, Pages 1131-1139

  Floege, J ^b   Grone H J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Glomerulonephritis; Progression; Proteinuria; Renal insufficiency; Renoparenchymal hypertension

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; DISEASE COURSE; HEMATURIA; HISTOPATHOLOGY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; ONSET AGE; PATHOGENESIS; PREVALENCE; PROGNOSIS; PROTEINURIA; RENOVASCULAR HYPERTENSION; CLINICAL PRACTICE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; GRAFT REJECTION; HUMAN; HYPERTENSION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; GLOMERULONEPHRITIS, IGA; GRAFT REJECTION; HEMATURIA; HUMANS; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROTEINURIA; RECURRENCE; TREATMENT OUTCOME;

EID: 1542599092     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1026-1     Document Type: Article

References (44)

1. Berger J, Neveu T, Morel-Maroger L (1967) Applications de l'immunofluorescence en nephrologie. Localisation des immunoglobulines et fibrinogene dans les lesions glomerulaires. Acta Nephrol Hop Necker 1: 172-175
2. Floege J, Feehally J (2000) IgA nephropathy: recent developments. J Am Soc Nephrol 11: 2395-2403
3. Donadio JV, Grande JP (2002) IgA nephropathy. N Engl J Med 347: 738-748
4. Varis J, Rantala I, Pasternack A et al. (1993) Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46: 607-610
5. Rai A, Nast C, Adler S (1999) Henoch-Schonlein purpura nephritis. J Am Soc Nephrol 10: 2637-2644
6. Schena FP (1990) A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89: 209-215
7. Ibels LS, Gyory AZ (1994) IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 73: 79-102
8. Eitner F, Schulze M, Brunkhorst R, Koch KM, Floege J (1994) On the specificity of assays to detect circulating immunoglobulin A- fibronectin complexes: implications for the study of serologic phenomena in patients with immunoglobulin A nephropathy. J Am Soc Nephrol 5: 1400-1406
9. Lanteri M, Wilson D, Savige J (1996) Clinical features in two patients with IgA glomerulonephritis and thin-basement-membrane disease. Nephrol Dial Transplant 11: 791-793
10. Schena FP, Cerullo G, Rossini M et al. (2002) Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 13: 453-460
11. Gharavi AG, Yan Y, Scolari F et al. (2000) IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 26: 354-357
12. Xie Y, Nishi S, Ueno M et al. (2003) The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63: 1861-1867
13. Allen AC, Bailey EM, Brenchley PE et al. (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60: 969-973
14. Tomana M, Novak J, Julian BA et al. (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73-81
15. Westerhuis R, Kitahara M, Daha MR, Floege J, Roos A (2003) Interaction of MBL with IgA induces complement activation on the surface of human mesangial cells. (submitted)
16. Ostendorf T, Kunter U, Groene HJ et al. (2001) Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12: 909-918
17. Kriz W, Hahnel B, Hosser H et al. (2003) Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol 14: 1904-1926
18. Johnson RJ, Alpers CE, Yoshimura A et al. (1992) Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474
19. D'Amico G (1988) Clinical features and natural history in adults with IgA nephropathy. Am J Kidney Dis 12: 353-357
20. Frimat L, Briancon S, Hestin D et al. (1997) IgA nephropathy: prognostic classification of end-stage renal failure. Nephrol Dial Transplant 12: 2569-2575
21. Bonnet F, Deprele C, Sassolas A et al. (2001) Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 37: 720-727
22. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207
23. Nolin L, Courteau M (1999) Management of IgA nephropathy: evidence-based recommendations. Kidney Int 70: S56-62
24. Floege J (2003) Evidence-based recommendations for immunosuppression in IgA-nephropathy: handle with caution. Nephrol Dial Transplant 18: 241-245
25. Kanno Y, Okada H, Saruta T, Suzuki H (2000) Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 54: 360-365
26. Pozzi C, Bolasco PG, Fogazzi GB et al. (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353: 883-887
27. Ballardie FW, Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: 142-148
28. Dillon JJ (1997) Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 8: 1739-1744
29. Floege J, Burg M, Kliem V (1998) Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant 13: 1933-1935
30. Hebert LA, Wilmer WA, Falkenhain ME et al. (2001) Renoprotection: one or many therapies? Kidney Int 59: 1211-1226
31. Russo D, Minutolo R, Pisani A, Esposito R et al. (2001) Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38: 18-25
32. Orth SR, Stockmann A, Conradt C W et al. (1998) Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 54: 926-931
33. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 124: 627-632
34. Fored CM, Ejerblad E, Lindblad P et al. (2001) Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345: 1801-1808
35. Harper L, Ferreira MA, Howie AJ et al. (2000) Treatment of vasculitic IgA nephropathy. J Nephrol 13: 360-366
36. Roccatello D, Ferro M, Cesano G et al. (2000) Steroid and cydophosphamide in IgA nephropathy. Nephrol Dial Transplant 15: 833-835
37. Shoji T, Nakanishi I, Suzuki A et al. (2000) Early treatment with cortcosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201
38. Tsuruya K, Harada A, Hirakata H et al. (2000) Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 53: 1-9
39. Hotta O, Miyazaki M, Furuta T et al. (2001) Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 38: 736-743
40. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 39: 493-502
41. McIntyre CW, Fluck RJ, Lambie SH (2001) Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 56: 193-198
42. Tamura S, Ueki K, Ideura H et al. (2001) Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 55: 192-195
43. Carruthers SG, Larochelle P, Haynes RB, Petrasovits A, Schiffrin EL (1993) Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ 149: 289-293
44. Brandenburg VM, Heintz B, Floege J (2003) Endorganschäden der Niere. Internist 44: 819-830